# China's NMPA Accepts Akeso's Ivonescimab Application for First-Line Biliary Tract Cancer

> China's NMPA accepted Akeso's application for ivonescimab plus chemotherapy in first-line biliary tract cancer, with Phase III survival of 14.9 months.

- Published: 2026-11-17T04:27:08+00:00
- Section: Regulation & Approvals
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-17/akeso-ivonescimab-biliary-tract-cancer-filing
- Source: [The future of trading](https://capital.com/en-int/news/china-accepts-akeso-s-ivonescimab-application-for-biliary-tract-cancer)

## Key takeaways

- China's NMPA accepted Akeso's application for ivonescimab with chemotherapy as first-line treatment for locally advanced or metastatic biliary tract cancer.
- The application had received priority review designation before acceptance.
- Phase III median overall survival was 14.9 months with ivonescimab versus 12.1 months with durvalumab, both combined with chemotherapy.

China's National Medical Products Administration accepted [Akeso Biopharma](https://akta.pro/company-profiles/000217r/akeso-biopharma)'s application for ivonescimab combined with chemotherapy as a first-line treatment for locally advanced or metastatic biliary tract cancer, [The future of trading](https://capital.com/en-int/news/china-accepts-akeso-s-ivonescimab-application-for-biliary-tract-cancer) reported on November 17, 2026. Akeso is a Chinese biopharmaceutical company listed in Hong Kong that develops antibody therapeutics in oncology, autoimmune and metabolic diseases, and sells two first-in-class bispecific antibodies, cadonilimab and ivonescimab, in China.

## Priority Review for the Biliary Tract Filing

The application had previously received priority review designation from the Chinese regulator. The filing covers ivonescimab given with chemotherapy in the first-line setting for patients whose disease is locally advanced or metastatic.

In Phase III testing, median overall survival reached 14.9 months with ivonescimab versus 12.1 months with durvalumab, with both regimens combined with chemotherapy. The company announced the acceptance through a release issued on November 17, 2026.

## Ivonescimab's Earlier Chinese Approval

According to akta.pro [company records](https://akta.pro/company-data), China's NMPA approved ivonescimab in April 2025 for first-line PD-L1 positive non-small cell lung cancer, based on Phase III HARMONi-2 data showing superiority over pembrolizumab with a progression-free survival hazard ratio of 0.51. The same records show Akeso and Shanghai Pharmaceuticals established a distribution partnership in September 2025 to widen commercialization reach for cadonilimab and ivonescimab across China. Full-year 2025 sales revenue rose 51.48% year on year to RMB 3,033.1 million, and the company raised $247.3 million in post-IPO equity in October 2026.

## Lung Cancer Data Against Pembrolizumab

Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2, Yahoo reported in September 2026. Interim HARMONi-2 results announced earlier that month showed ivonescimab beat Merck's Keytruda in first-line non-small cell lung cancer with PD-L1 expression, at 11.14 months progression-free survival versus 5.82 months, BioSpace reported. The FDA was set to decide on Summit/Akeso's ivonescimab in November 2026, BioSpace reported on November 6, 2026.

## What Comes Next for Akeso

The FDA decision on Summit/Akeso's ivonescimab was scheduled for November 14, 2026, according to BioSpace. Akeso's own announcement of the Chinese acceptance was published on November 17, 2026, on its [company website](http://www.akesobio.com).

## Companies in this story

- [Akeso Biopharma company profile](https://akta.pro/company-profiles/000217r/akeso-biopharma) · website: http://www.akesobio.com

---
News for Agent · https://newsforagent.com/llms.txt
